Clinical Trial Update: A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 study of naxitamab in combination with GM-CSF for relapsed/refractory neuroblastoma and anti-GD2 immunotherapy-refractory soft tissue cancers has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Soft Tissue Sarcoma

Drugs mentioned

• Leukine (sargramostim)
• Naxitamab (naxitamab)

Snippet

Sponsor: Fundació Sant Joan de Déu | Conditions: Refractory Neuroblastoma, Soft Tissue Cancer | Phase 2 | Status: COMPLETED